A case of testotoxicosis due to a constitutive mutation of the LH receptor initially presented as a central precocious puberty at 3 years old.

Valérie Porquet-Bordes 1, C. Piennkowski 1, N. De Roux 2
1 Department of Endocrinology and Bone Diseases, Children’s Hospital, CHU Toulouse, France, 2 Department Biochemistry and hormoneology, CHU Robert Debré Paris, France

BACKGROUND
A thirty four months old boy was referred for precocious puberty. He was the first child of healthy non-consanguineous parents. His father was suspected to have enlarged testis during early childhood, without any investigation. His final height was 180 cm, incompatible with precocious puberty. The boy had no exposure to oestrogenic endocrine-disrupting chemicals. He had presented secondary sexual characteristics for five months: pubic hair, enlarged testicular volume to 6 ml (Tanner stage P2A1G2) and enlarged penile size. He had a deepening voice and aggressive behavior. He had a significant growth acceleration with an advanced bone age (six years according to the Grulich and Pyle atlas). His height was 103 cm (3 SDS).

LABORATORY INVESTIGATIONS
The testosterone level was high: 190 ng/dl. The gonadotrophin hormone-releasing hormone stimulation test revealed a baseline LH and FSH of 0.1 UI/l and peaks levels of LH at 2.6 UI/l and of FSH at 1.2 UI/l. The AMH level was 26.6 ng/ml. Inhibine was 189 ng/ml. The IGF-1 level was high, correlated to the testosterone level: 306 ng/ml (3 DS). The adrenal function was normal. Tumor markers, alfa-fetoprotein and beta-human chorionic gonadotrophin, were normal. Ultrasound of the testis and the adrenal revealed no tumor. The brain MRI excluded a tumor of the hypothalamus or the pituitary gland.

EVOLUTION AND MANAGEMENT
The diagnosis of central precocious puberty was made and a treatment with monthly intramuscular injections of gonadotrophin releasing hormone analog (GnRHa) was started. Three months later, no clinical improvement was noticed: testicular volume progressed to 8ml, and height was 109 cm (4 DS) (Fig1). LH and FSH Baseline levels were 0.7 UI/l, and 0.1 UI/l respectively. The testosterone level increased to 311 ng/dl with a lowering AMH level at 12.3 ng/ml. GnRHa treatment was switched to long action every three months associated first to cyproterone acetate and then to ketoconazole. Ketoconazole has been introduced on month 5 and was quickly efficient to control testosterone levels (Fig 2).

CONCLUSION
This case of testotoxicosis is unusual as it initially presented as a central precocious activation of the gonadotropic axis at a very young age, with enlarged testis. Due to resistance to GnRHa agonist treatment, the diagnosis of constitutive activation of the LH receptor was then suspected and confirmed by molecular genetics. The penetrance of the M398T mutation is incomplete in that family, other factors may influence the clinical expression. Activating mutations of the LH receptor are heterogenous. The response to ketoconazole on inhibiting adrenal and androgen biosynthesis, is mutation-dependant. That boy presenting the M398T mutation is sensitive to ketoconazole, with good hepatic tolerance, as previously described in a French cohort [2]. The case questions also about the cellular mechanism of the central activation of the gonadotropic axis.

BIBLIOGRAPHY

Fig1 - Growth curves
Fig2 - Evolution under treatment